Capitalstars Updates: Top Corporate News :- 30 Jan 2018

Top Headlines Of The Day:- 30 Jan 2018

Jubilant receives ANDA approval for Clonidine Hydrochloride ER Tablets

KPIT and Birlasoft to come together to create two entities

Mylan and Biocon receive positive CHMP opinion for Insulin Glargine

Amber Enterprises lists at 38% premium to issue price

HCL Tech gets 5-year order from Cadent for IT Infra services

Jubilant receives ANDA approval for Clonidine Hydrochloride ER Tablets
Jubilant Life Sciences has announced that its material wholly owned subsidiary Jubilant Pharma Limited has received Abbreviated New Drug Application (ANDA) final approval for Clonidine Hydrochloride Extended-Release Tablets, 0.1 mg. This is a generic version of Kapvay of Concordia. It is used for the treatment of attention deficit hyperactivity disorder (ADHD).
As on December 31, 2017, Jubilant had a total of 86 ANDAs for Oral Solids filed in the US of which 56 had been approved and 12 Injectable filings of which 10 had been approved. This is the eighth USFDA approval in FY18.

Clonidine Hydrochloride Extended-Release Tablets, 0.1 mg had annual sales of ~USD 66 million in the US as per IMS MAT Jun 2017. 

KPIT and Birlasoft to come together to create two entities
KPIT Technologies had informed the exchanges that its board had approved a draft composite scheme for amalgamation of Birlasoft (India) with KPIT. The second leg of the transaction would involve demerger of the engineering business of the company into KPIT Engineering Limited (KEL), a wholly owned subsidiary of the company and will be renamed as KPIT Technologies Limited.
According to the arrangement, shareholders of Birlasoft will receive 22 equity shares of the combined KPIT -Birlasoft for every nine equity shares of Birlasoft. the combined KPIT-Birlasoft will be engaged in the ITSS Business, and pursuant to the Proposed Demerger, KEL's shares will be listed and shareholders of combined KPIT-Birlasoft will receive one share of KEL for each share they hold in the combined KPIT-Birlasoft.

Mylan and Biocon receive positive CHMP opinion for Insulin Glargine
Biocon has announced that it, along with its partner Mylan, has received a positive opinion from Europen Medical Agency’s (EMA) - Committee for Medicinal Products for Human Use (CHMP) - for insulin Glargine. CHMP has also recommended approval to Insulin Glargine, which will be sold under brand Semglee.
There are ~60m people affected by diabetes in Europe with an increasing prevalence in the region. Insulin Glargine is a biosimilar, which will be available for commercialization once it receives EMA approval.
Biocon and Mylan are also awaiting approval for Insulin Glargine in Australia, Canada, and the US and are planned for key Emerging Markets.

Amber Enterprises lists at 38% premium to issue price
Amber Enterprises listed at a significant premium of 38% to its issue price of Rs855-859 and is currently trading at Rs1, 187.2.
The IPO offer consisted of Fresh Issue of 55.3 lakh shares (aggregating up to ~Rs475cr) at the upper end of the price band. It also includes an offer for sale of up to 14.6 lakh shares (Rs125cr) by the promoters. The issue proceeds will be used for pre-payment or repayment of borrowings (~Rs400cr) and for other general corporate purposes (~Rs75cr).

HCL Tech gets 5-year order from Cadent for IT Infra services
HCL Technologies (HCL) announced a five-year IT infrastructure services and application management contract with Cadent, the UK’s largest gas distribution network. The ground-breaking ‘cloud first’ multi-service deal will see HCL provide integrated public cloud hosting and SAP and Application Maintenance Services, including the migration of a significant applications portfolio to Amazon Web Services (AWS) public cloud. In addition, HCL will provide IT Service Management, Service Desk and Managed Workplace Services.
HCL will deliver these services to support Cadent’s business operations which distributes gas to 11 million homes and businesses in the North West, Midlands, East and South East of England. HCL will provide MWS support to approximately 4,500 staff; including 3,500 field based-engineers who work across the company’s 65 regional depots.

MCX Tips,  Intraday Stock Tips ,  Equity Tips  , Free Trading Tips , Sebi Regsitred Advisory Company , Capitalstars Video Gallery

Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

CapitalStars Success Story On CNBC Awaaz Kamyabi Ki Raah: 30 Jan 2018

CapitalStars Award Winning, SEBI registered, ISO certified investment advisory company. We provide intraday & positional services in equity , derivative ,commodity & currency. Our research team is highly skilled & experienced 

Please Contact 0731-6690000.

Reach Us at:- http://capitalstars.com/video-gallery

MCX Tips,  Intraday Stock Tips ,  Equity Tips  , Free Trading Tips , Sebi Regsitred Advisory Company , Capitalstars Video Gallery

Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

Capitalstars Updates: Top Corporate News :- 29 Jan 2018

Top Headlines Of The Day :- 29 Jan 2018

Avenue Supermarts Ltd (DMart), up 5% after announcing Q3FY18 results, PAT up 65.8% yoy
Cipla, Aurobindo and Strides Shasun receive final approval for gViread
Havells to set up a manufacturing unit in Rajasthan for an investment of Rs360cr
DLF is looking to launch QIP of shares by April, 2018
Idea Cellular seeks government approval for raising FDI limit to 100%

Avenue Supermarts Ltd (DMart), up 5% after announcing Q3FY18 results, PAT up 65.8% yoy
DMart rallies 5% after announcing Q3FY18 results. In Q3FY18, its revenue grew by 22.6% yoy to Rs4, 095cr. EBITDA came in at Rs422cr, up 46.3% yoy . EBITDA margin expanded by 167bps yoy to 12.3% due to an improvement in sales mix and efficiency of centralized procurement. Adjusted PAT increased by 65.8% yoy to Rs252cr.
Board has also approved acquisition of 50.8% paid-up share capital of Avenue E-Commerce Limited for Rs49.2cr. Post-acquisition it will become wholly owned subsidiary. Heavy discounts to attract price sensitive customers and losses of the e-commerce entity will offset the margin gains.

Cipla, Aurobindo and Strides Shasun receive final approval for gViread
Cipla, Aurobindo and Strides Shasun have received final approval for their Abbreviated New Drug Application (ANDA) for Tenofovir Disoproxil Fumarate Tablets, 300mg, from the USFDA. This is a generic version of Gilead Sciences' Viread Tablets, 300mg which is indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in adults. The final approval means that product is available for immediate commercialization in the US.
Viread 300mg tablets had annual US sales of approximately $725-750mn as per IMS Health. An orange book search on USFDA website indicates that Aurobindo, Cipla, Teva, Macleods Pharmaceuticals and Strides Shasun, all have received approval for this drug on January 26, 2018. Approval for five different filers on the same day is likely to see competition for the Viread 300mg tablets.

Havells to set up a manufacturing unit in Rajasthan for an investment of Rs360cr
Havells is setting-up a new facility at Ghiloth, Neemrana, Rajasthan to manufacture consumer durables, as per the BSE filing. The total estimated cost for the project is Rs360cr (ex-land cost, as the company already owns the land), spread over a period of 3 years. The total investment will be funded through a mix of internal accruals and borrowings. Company expects to start the production from Q3FY19E.
For this investment, the company will be entitled to investment subsidy under the M-SIPS (Modified Special Incentive Package Scheme) introduced by MEITY and also for various tax/ levies and other benefits from the State Government of Rajasthan.

DLF is looking to launch QIP of shares by April, 2018
DLF is looking to launch its qualified institutional placement (QIP) of shares by April 2018, according to a media report.
DLF has already received approval from shareholders to sell 173-million equity shares, which will be determined by the formula laid down by the market regulator Securities and Exchange Board of India. The company may raise Rs4500-5000cr from the QIP.

Idea Cellular seeks government approval for raising FDI limit to 100%
Telecom operator Idea Cellular has made an application to the DIPP (Department of Industrial Policy and Promotion) for raising the FDI limit in Idea to 100%. Foreign investors holdings in Idea Cellular stood at ~27% stake as on December 2017. While 100% FDI is allowed in telecom companies, investments under the automatic route are allowed up to 49%.
At present, Idea Cellular is in the process of merging its telecom business with the Indian unit of Vodafone. As per latest industry data from Trai, Idea and Vodafone jointly have 40.5cr mobile subscribers. This would potentially give the joint entity the largest subscriber base in the Indian telecom segment. Vodafone is expected to hold around 47.5% stake in the merged entity and rest will be owned by Idea and its promoter Aditya Birla Group.

MCX Tips,  Intraday Stock Tips ,  Equity Tips  , Free Trading Tips , Sebi Regsitred Advisory Company , Capitalstars Video Gallery

Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

Birla MF Co-CIO Patil sees low teens 2018 growth for Nifty, likes auto, consumer durables, telecom:- 27 Jan 2018

Considering the government’s long-term vision, and the trend set through earlier budgets, the focus of the upcoming Union Budget is likely to remain largely on infrastructure and the rural economy, believes Mahesh Patil, Co-Chief Investment Officer-equities at Aditya Birla Sun Life Mutual Fund.

In an exclusive interview to Moneycontrol, Patil said that investors should not expect a repeat of 2017 in terms of returns, since the Nifty returned as much as 29 percent in the year. It is unlikely to happen again in 2018

We saw a good run up in 2017. How do you see markets panning out in 2018?

2018, as we step forward into this new calendar year, things are looking much better. A lot of things have fallen into place. Last year, we went through ups and downs. The economy took kind of a beating, but the gains of all the reforms would start to unfold and we are expecting a pretty good recovery back in corporate earnings.

Global outlook continues to remain fairly stronger than it was after the global financial crisis. So, all these tailwinds should continue to favour the markets. Since we did very well last year, the return expectations would probably have to be moderated down now because we are starting from a higher valuation level and to that extent, the market returns this calendar year would probably be muted compared to last year. But still, our view is that returns should be fairly good for investors to look positively at equities compared to any other asset class.

According to your presentation GDP, growth will be more than 7 percent in FY19. Is that achievable?

Yes, it is fairly achievable because the growth was pulled down because of reforms. We are seeing some recovery in capital expenditure, at least private sector capex will slowly start to pick up, though not in a big way. But at least the lower end will and rural consumption is moving up. Global growth is also fairly strong. So, even the net exports should be fairly good. So 7 percent GDP growth, considering all these factors, should quite be possible.

MCX Tips,  Intraday Stock Tips ,  Equity Tips  , Free Trading Tips , Sebi Regsitred Advisory Company , Capitalstars Video Gallery

Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

CapitalStars Investment Adviser: SEBI Registration Number: INA000001647